Description: Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA), the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.
Home Page: www.spectraldx.com
135 The West Mall
Toronto,
ON
M9C 1C2
Canada
Phone:
416-626-3233
Officers
| Name | Title |
|---|---|
| Mr. Christopher Seto | CEO & Director |
| Dr. John A. Kellum M.D. | Chief Medical Officer |
| Ms. Debra-Anne M. Foster B.Sc., RN, CCRC | VP of Clinical Devel. |
| Mr. Blair McInnis | Chief Financial Officer |
| Mr. Sam Amory | Pres of Dialco Medical Inc. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 51.7293 |
| Price-to-Sales TTM: | 42.7504 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |